ACTISINU Headache and Fever Cold and Nasal Congestion 12 capsules/box

Description

Main ingredients

Active ingredients of one tablet: 200 mg of ibuprofen, 30 mg of pseudoephedrine hydrochloride. Excipients: microcrystalline cellulose, anhydrous calcium hydrogen phosphate, cross-linked sodium carboxymethyl cellulose, corn starch, anhydrous colloidal silicon dioxide, magnesium stearate.

Indications

ACTISINU 12 Tablets is a drug with anti-inflammatory and vasoconstrictive effects for the symptomatic treatment of nasal congestion associated with fever and headache due to colds in adults and adolescents over 15 years of age. It is recommended only when both of the following symptoms are present: nasal obstruction or headache or fever.

Dosage

We recommend taking 1 tablet every 6 hours. If symptoms are more severe, we recommend taking 2 tablets every 6 hours.

The maximum total daily dose should not exceed 6 tablets (equivalent to 1200 mg of ibuprofen and 180 mg of pseudoephedrine hydrochloride). Treatment should not exceed 5 days.
Method of administration: oral use.
Tablets should be swallowed with water, preferably on a full stomach. Do not crush the tablets.
Caution

PROHIBITIONS.
Hypersensitivity to ibuprofen, pseudoephedrine or any excipients; patients younger than 15 years; pregnancy and breastfeeding; history of hypersensitivity reactions (e.g., bronchospasm, asthma, nasal polyps, rhinitis or urticaria). History of peptic ulcers or recurrent ulcers/bleeding (two or more significant ulcer episodes or signs of bleeding) History of gastrointestinal bleeding or perforation, including cases associated with NSAID Cerebrovascular hemorrhage or other type of bleeding. Unexplained hematopoietic abnormalities.

Severe renal insufficiency.
Severe hepatic insufficiency.
Severe heart failure.
Severe cardiovascular disease, coronary artery disease (heart disease, hypertension, angina), tachycardia, hyperthyroidism, diabetes mellitus, pheochromocytoma, history of stroke or presence of stroke risk factors (due to alpha-sympathomimetic activity of pseudoephedrine hydrochloride).
Closed-angle glaucoma.
Risk associated with uroprostatic disease.
History of myocardial infarction.
History of epilepsy.

Systemic lupus erythematosus.
And other vasoconstrictive drugs administered transnasally or nasally (e.g., phenylpropanolamine, phenylephrine, and ephedrine) and methylphenidate as nasal congestion agents.